Intravenous ganaxolone for the treatment of refractory status epilepticus: Results from an <scp>open‐label</scp> , <scp>dose‐finding</scp> , phase 2 trial-Reference-Cited by-同舟云学术

Intravenous ganaxolone for the treatment of refractory status epilepticus: Results from an open‐label , dose‐finding , phase 2 trial

Author:

Vaitkevicius Henrikas¹²^ORCID,Ramsay R. Eugene³,Swisher Christa B.⁴,Husain Aatif M.⁵⁶,Aimetti Alex²,Gasior Maciej²

Affiliation:

1. Department of Neurology Brigham and Women's Hospital Boston Massachusetts USA

2. Marinus Pharmaceuticals Radnor Pennsylvania USA

3. International Center for Epilepsy St. Bernard Hospital New Orleans Louisiana USA

4. Carolinas Medical Center Atrium Health Charlotte North Carolina USA

5. Department of Neurology Duke University Durham North Carolina USA

6. Neurodiagnostic Center Veterans Affairs Medical Center Durham North Carolina USA

Funder

Marinus Pharmaceuticals, Inc.

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Link

Reference53 articles.

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

3. Emergent Management of Status Epilepticus;CONTINUUM: Lifelong Learning in Neurology;2024-06

4. Childhood Epilepsies and When to Refer for Epilepsy Surgery Evaluation;Common Childhood Diseases - Diagnosis, Prevention and Management [Working Title];2024-05-23